BridgeBio Pharma Presents Updated Results of Acoramidis (AG10) in P-II OLE Study for Transthyretin Amyloid Cardiomyopathy at ACC 2022
Shots:
- The ongoing P-II OLE study evaluates acoramidis (800Mg, bid) in 47 patients with ATTR-CM with NYHA class II or III symptoms who had completed the 28-day P-II study
- The results showed a near-complete TTR stabilization as measured by established ex vivo assays and increased serum TTR levels, median NT-proBNP was stable or improving throughout the study, median change from baseline in NT-proBNP was -437 pg/mL @30mos. with 68% had NT-proBNP levels below their baseline, improvement in heart failure severity
- Additionally, 31 out of 47 patients remained in the OLE study, patients discontinued (16 ) & were well-tolerated with no safety signals. The results from an ongoing P-II (ATTRibute-CM) trial of acoramidis are expected in mid-2023
Ref: Globe Newswire | Image: BridgeBio Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
